LAssa Fever Adjunct Treatment With DEXamethasone

Launched by BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE · Jan 15, 2024

Keywords

ClinConnect Summary

The clinical trial titled "LAssa Fever Adjunct Treatment With DEXamethasone" is studying the use of a medication called dexamethasone to help treat Lassa Fever, a serious viral infection. Dexamethasone is a type of steroid that can reduce inflammation and may help improve health outcomes for patients with severe cases of Lassa Fever. The trial is currently looking for adult participants aged 18 and older who have been diagnosed with Lassa Fever and are experiencing significant health issues, such as low blood pressure, confusion, or serious liver problems.

If you or a loved one are considering joining this trial, you would need to meet certain criteria, including having a confirmed diagnosis of Lassa Fever and showing signs of serious illness. Participants will receive treatment and be closely monitored by healthcare professionals throughout the study. It's important to note that pregnant women, those breastfeeding, and individuals who have recently taken similar medications may not be eligible to participate. This trial aims to find out if dexamethasone can be an effective addition to the treatment for Lassa Fever, potentially leading to better care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • LF confirmed by RT-PCR (reverse-transcription polymerase chain reaction) with a cycle threshold (Ct) value \< 30
• * Signs of significant health impairment as evidenced by any of the following:
• • Alert, confusion, voice, pain, unresponsive (ACVPU) other than A
• • Systolic blood pressure \< 90 mmHg
• • Seizure(s), meningism, coma, focal neurological deficit
• • AST (GOT) \>3xULN
• • ALT (GPT) \> 3xULN
• • KDIGO 2 or more severe based on serum creatinine only
• • Active macroscopic bleeding
• • O2 saturation \< 92
• Exclusion Criteria:
• • Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)
• • Lactation following live birth
• • Known intolerance and contra-indications to ribavirin or dexamethasone
• • Patients who already received a corticosteroid within the preceding 7 days
• • Investigator's valuation that patient might be put to substantial risk by participating in this trial
• • Patients receiving end-of-life care as judged by the investigator